What Are Tumor Marker Rapid Tests?

A tumor marker POCT test rapidly measures substances that may be elevated in the presence of certain conditions. Prostate-specific antigen (PSA) relates to prostate health; carcinoembryonic antigen (CEA) is used mainly in colorectal and some other contexts; alpha-fetoprotein (AFP) relates to liver and germ-cell conditions; and fecal occult blood (FOB) detects hidden blood in stool as an adjunct in colorectal assessment.

It is essential to understand the limits of these tests. A tumor marker is not specific to cancer: levels can rise in benign conditions (for example, PSA in prostatitis or benign enlargement; AFP in non-malignant liver disease), and a normal result does not exclude malignancy. These kits are not a cancer diagnosis and a tumor-marker rapid test is not a substitute for guideline-based cancer screening. Any abnormal result must be followed up and interpreted by a qualified clinician with appropriate confirmatory work-up.

Standard Tumor Marker Rapid Test Procedure

A point-of-care protocol for professional use. Always follow the IFU of the specific marker and format; results require clinical interpretation.

Collect Sample

Collect whole blood, serum or plasma (or a stool sample for FOB) per the kit IFU.

Prepare Sample

Transfer the specified volume into the buffer/diluent as described in the IFU.

Apply to Device

Add the prepared sample to the cassette well, or load the cartridge into the fluorescence analyzer.

Read & Refer

Read visually within the stated time, or read the quantitative value from the analyzer. Interpret against reference ranges in the IFU and refer abnormal results for clinical evaluation.

Fluorescence Immunoassay & Quantitative Technology

Our tumor marker fluorescence immunoassay platform pairs dry-fluorescence cartridges with a compact analyzer to report exact PSA, CEA and AFP concentrations in minutes, while colloidal gold formats provide rapid qualitative screening where a numeric value is not required — both designed for professional point-of-care workflows.

Certifications & Regulatory Approvals

Our respiratory pathogen panels are manufactured under a certified quality management system and cleared in major global markets.

Where Are Tumor Marker Rapid Tests Used?

Engineered to support infection control protocols across all levels of the healthcare infrastructure.

Oncology Follow-Up

Support monitoring of marker trends in patients already under specialist care.

Symptomatic Risk Assessment

Aid clinicians evaluating patients with relevant symptoms, as one input among many.

Laboratory & POCT

Fast quantitative results to support clinical decision-making, not standalone diagnosis

Distributors & OEM Brands

Branded PSA/CEA/AFP/FOB ranges for professional clinical channels worldwide.

Frequently Asked Questions & Solutions

What do PSA, CEA, AFP and FOB tests measure?

These four tests are crucial in vitro diagnostic (IVD) tools primarily used for early cancer screening, diagnosis, and disease monitoring. Here is exactly what each test measures:
PSA (Prostate-Specific Antigen): Measures the level of PSA protein in the blood, which is produced by the prostate gland. It is the primary screening tool used to detect and monitor prostate cancer, as well as other benign prostate conditions.
CEA (Carcinoembryonic Antigen): Measures the amount of CEA protein in the bloodstream. It acts as a broad-spectrum tumor marker, most commonly used to monitor the progression and treatment of colorectal cancer, though it is also associated with lung, breast, and pancreatic cancers.
AFP (Alpha-Fetoprotein): Measures the AFP level in the blood. In adult diagnostics, elevated AFP is a critical primary marker used to screen for and monitor liver cancer (Hepatocellular Carcinoma) and certain germ cell tumors.
FOB (Fecal Occult Blood): Detects microscopic, hidden blood in a stool sample that cannot be seen by the naked eye. It is a highly effective, non-invasive early screening tool for gastrointestinal bleeding and colorectal cancer.

Can a tumor marker rapid test diagnose or rule out cancer?

No. Tumor markers are not cancer-specific. Levels can rise in benign conditions (for example, PSA in prostatitis or benign prostatic hyperplasia; AFP in non-malignant liver disease such as hepatitis), and a normal result does not exclude malignancy. These rapid tests are screening and monitoring aids only — they are not a substitute for guideline-based cancer screening programs (such as colonoscopy, mammography, or imaging), and any abnormal result must be followed up with confirmatory diagnostic work-up by a qualified clinician.

Should I use a PSA test at home to check for prostate cancer myself?

A PSA result alone cannot confirm or exclude prostate cancer and is commonly elevated by non-cancerous prostate conditions. PSA should be discussed with and interpreted by a healthcare professional, not used for self-diagnosis

Tumor Marker Solutions

Partner with a vertically integrated IVD factory in China for a wholesale tumor marker test kits supply. We provide end-to-end customization — PSA, CEA, AFP and FOB devices in colloidal gold or fluorescence formats, with branded packaging and multi-language IFUs — for distributors and diagnostic brands worldwide.

Custom Multiplex Panels

Combine specific parameters (e.g., SARS-CoV-2 + Flu A/B + RSV + ADV) into a single 3-in-1, 4-in-1, or 5-in-1 test cassette based on your regional epidemiological demands.

Private Label & Packaging

Full artwork design services for foil pouches, multi-language IFU inserts (Instructions for Use), and external retail cartons tailored to your brand identity.

Regulatory Filing Support

We provide comprehensive technical documentation, performance validation studies, and clinical data to expedite your local Ministry of Health or CE IVDR registrations.